ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1

Controlled Clinical Trials

Volumn 22, Issue 2, 2001, Pages 142-159

  Smeaton, Laura M ^a   DeGruttola, Victor ^a   Robbins, Gregory K ^b   Shafer, Robert W ^c  

^a CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AIDS; Clinical trials design; Controlled; Double blind trial; Multicenter; Phase III study; Randomized

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD38 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; DIDANOSINE; EFAVIRENZ; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NUCLEOSIDE DERIVATIVE; PADGEM PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; ITALY; MALE; MIDDLE AGED; MULTICENTER STUDIES; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS; REVERSE TRANSCRIPTASE INHIBITORS; SALVAGE THERAPY; UNITED STATES;

EID: 0035068386     PISSN: 01972456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-2456(00)00126-4     Document Type: Article

References (30)

1. Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in subjects with HIV-1 infection
2. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
3. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
4. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
5. Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection
6. 3
7. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults
8. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society
9. Failure of HIV-1 protease inhibitors to fully suppress viral replication. Implications for salvage therapy
10. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
11. Resistance to human immunodeficiency virus type 1 protease inhibitors
12. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients
13. Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine
14. Drug resistance and virological response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients
15. Viral dynamics of HIV: Implications for drug development and therapeutic strategies
16. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up
17. Rebound of HIV-1 viral load after suppression to very low levels
18. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations
19. Efficient trial designs for studying combination antiretroviral treatments in patients with various resistance profiles
20. Trial design in the era of highly effective antiviral drug combinations for HIV infection
21. Sample size calculations for failure time data
22. Adjusting for nonignorable drop-out using semiparametric nonresponse models
23. Ranking procedures for arbitrarily restricted observations
24. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
25. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan